Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomised, double-blind, placebo-controlled study of EPA-FFA in familial adenomatous polyposis
2017-002809-34Phase 3Completed
- Sponsor
- SLA Pharma
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Colonic Adenomatous Polyposis comparing EPA-FFA gastro-resistant capsules with Placebo (2 arms). Primary endpoint: Total number of polypectomies in rectum (polyps > 5 mm). Started Mar 2018; status: completed.
02
Drugs
eicosapentaenoic acid
03
Conditions
Colonic Adenomatous Polyposis
Beyond the preview
Go deeper on 2017-002809-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002809-34.